The company collaborates with over 250 partners, including pharmaceutical and biotechnology companies, to address various disease targets. Numerion Labs developed APEX to address the inability to comprehensively search chemical space at scale, pairing deep learning surrogates with GPU-accelerated enumeration to virtually evaluate billions of potential starting points in seconds.
Cyborg Score Rationale
Numerion Labs has raised $246M in total funding. The company has strong validation through a 318-target study across 250+ labs showing 73-75% project-level success and large collaborations with Sanofi (up to $1.2B in milestones) and partnerships with Eli Lilly, Bayer, and others. Recent APEX technology advancement (October 2025) demonstrates continued innovation in GPU-accelerated virtual screening.
Top Insights
AtomNet platform evaluation in 318-target virtual screening study across 250+ academic labs reported success rates of 74-75% and hit rates of 5-6% even without prior actives.
APEX technology enables virtual evaluation of billions of molecules in seconds, ensuring promising compounds are not overlooked in comprehensive chemical space exploration.
250+ pharmaceutical and biotechnology partners validate market adoption and demand for Numerion's capabilities across diverse disease targets.
Company specializes in structure-based virtual screening for small-molecule hits, differentiated from competitors by focus on hit discovery rather than end-to-end pipeline coverage.
Named Competitors
BenevolentAI — AI-driven target and indication discovery using knowledge-graph biology
Insilico Medicine — End-to-end generative AI drug discovery pipeline with autonomous lab
Exscientia — AI-powered drug discovery platform with multiple clinical programs
X-37 — AI drug discovery platform
Recent Developments
(October 2025) Published breakthrough APEX research with NVIDIA on ultra-fast screening of billions of virtual molecules in seconds, advancing GPU-accelerated chemical space enumeration
(October 2025) Rebranded from Atomwise to Numerion Labs, consolidating focus on ultra-fast virtual screening and immune/inflammatory disease programs
(June 2024) Mentioned in CB Insights research on Sanofi's growth strategy and faster drug-to-market approaches
Open the full interactive Numerion Labs report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.